Kornimate/medical-research-clean huggingface dataset:
identification of hematological malignancies and therapy predication using micrornas as a diagnostic tool

Conditions: Lymphoma, B-Cell; Follicular Lymphoma; Hodgkin Lymphoma; Multiple Myeloma

Summary: mirnas are small (\~19-25 nucleotides) non-coding rna molecules that bind to mrna in a sequence-specific manner. mirnas regulate gene expression at the post-transcriptional level. mirnas regulate critical cell processes such as metabolism, apoptosis, development, cell cycle, hematopoietic differentiation and have been implicated in the development and progression of several types of cancers, including hematological malignancies. over-expression, amplification and/or deletion of mirnas and mirna-mediated modification of epigenetic silencing can all lead to oncogenic pathways. hematologic cancers, which are caused by the malignant transformation of bone marrow cells and the lymphatic system, are usually divided into three major clusters: leukemia, lymphoma, and multiple myeloma. to date, some of the hematological malignancies are very aggressive that early diagnosis is essential for improving prognosis and increasing survival rates. however, current diagnostic methods have various limitations, such as insufficient sensitivity, specificity, it is also time-consuming, costly, and requires a high level of expertise, which limits its application in clinical contexts. thus, development of new biomarkers for the early detection and relapse of hematological malignancies is desirable. some of the innate properties of mirnas make them highly attractive as potential biomarkers. mirnas can be readily detected in small volume samples using specific and sensitive quantitative real-time pcr; they have been isolated from most body fluids, including serum, plasma, urine, saliva, tears and semen and are known to circulate in a highly stable, cell-free form. they are highly conserved between species, allowing the use of animal models of disease for pre-clinical studies. furthermore, tumor cells have been shown to release mirnas into the circulation and profiles of mirnas are altered in the plasma and/or serum of patients with cancer. a growing number of publications confirm that mirnas can be a useful biomarker for hematological malignancies diagnosis and progression.


Eligibility criteria:
inclusion criteria: * newly diagnose patients with: diffused large b cell lymphoma, follicular lymphoma, multiple myeloma and hodgkin lymphoma. * patients after chemotherapy (5-30 days). * above age 18. exclusion criteria: * non-hiv/hcv/hbv below age 18.
calibr-ì: comparative evaluation of phantomless calibration methods to quantify bone mineral density for opportunistic analysis of ct scans

Conditions: Osteoporosis

Summary: osteoporosis is a systemic disease characterized by a reduction in bone mineral density (bmd) and qualitative alteration of the skeleton, resulting in increased bone fragility and fracture risk. the epidemiological impact of osteoporosis is extremely high. proper diagnosis and clinical management of osteoporosis are critical to reducing the incidence of fragility fractures and preventing their complications. the diagnosis is generally confirmed by instrumental analysis of bone mineral density. the standard method is x-ray bone densitometry (dxa), which allows diagnosis based on criteria defined by the world health organization (who) by virtue of the t-score. dxa is a relatively quick and inexpensive examination with low exposure to ionizing radiation. however, this method has limitations in detecting fracture risk, and in addition, not all patients are properly referred for dxa services, which, among other things, require specific criteria to be reimbursed by the national health system. currently, computed tomography (ct) scanning is the most widely used three-dimensional diagnostic modality in clinical practice, and the number of investigations performed in high-income countries is continuously growing. quantitative assessment of bone mineral density by ct is possible by proper calibration of the machine for the purpose of converting the ct numbers (or hounsfield units) measured by the scanner into bmd units.


Eligibility criteria:
inclusion criteria: * both sexes. * all ethnicities. * age equal or above 18 years. * any clinical indication (no specific pathology is required) for a ct scan of the lumbosacral spine or abdomen in which the entire lumbar spine (l1 to l5), paravertebral muscles, abdominal aorta, and subcutaneous adipose tissue are visible. * ability to give informed consent. exclusion criteria: * general contraindications to ct examination, including pregnancy or body weight/size exceeding scanner limits. * severe degenerative manifestations of the lumbosacral spine. * severe scoliosis of the lumbosacral spine. * surgical hardware that prevents adequate ct scanning. * oncologic pathology in progress or in recent history. * any other situation deemed incompatible with the study by the designated physician or investigator.
inhaled treprostinil in sarcoidosis patients with pulmonary hypertension

Conditions: Sarcoidosis; Precapillary Pulmonary Hypertension; Interstitial Lung Disease

Summary: this study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.

pulmonary sarcoidosis-associated pulmonary hypertension is classified as who group 5 pulmonary hypertension and may occur in anywhere from 5-20% of sarcoidosis patients. inhaled treprostinil has shown clinical improvements in exercise capacity after 12 weeks of therapy in patients with who group 1 pulmonary hypertension. more recently, there has been interest in using inhaled pah-specific therapies for the treatment of pulmonary hypertension associated with interstitial lung disease. the investigators believe that those patients with pulmonary hypertension in the setting of sarcoidosis-associated interstitial lung disease are a unique population which may potentially benefit from inhaled, targeted pulmonary arterial hypertension therapy (inhaled treprostinil) while minimizing the adverse effects associated with systemic pulmonary vasodilators. this study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.

Eligibility criteria:
inclusion criteria: * study participant willing and able to provide informed consent * negative urine pregnancy test at baseline for females of childbearing potential * established diagnosis of sarcoidosis by ats/ers/wasog 1999 statement on of sarcoidosis * presence of interstitial lung disease by scadding stage iv chest radiograph or extensive fibrosis on chest computed tomography * right heart catheterization within six months of baseline visit showing precapillary pulmonary hypertension (mpap ≥ 25 mmhg, pcwp ≤ 15 mmhg, and pvr \> 3 wu) * patient on stable sarcoidosis therapy for at least three months prior to screening * if patients are on oral pah therapy (pde5i/scgs and/or era) then dose should be stable for at least three months prior to screening * a 6mwt within three months of screening visit of \> 100 meters exclusion criteria: * pregnant patients or those who are actively lactating * patient not willing to use form of birth control (if applicable) during the study * inability to undergo 6mwt, rhc, pfts or cmri * predicted survival \< 6 months * patient on any prostanoid or prostanoid analog therapy * patients with left sided heart disease as defined by either a pcwp \> 15 mmhg and/or left ventricular ejection fraction \< 40% * use of any investigational drug/device, or participation in any investigational study with therapeutic intent within 30 days prior to randomization.

Keywords: right heart catheterization (rhc) pulmonary vascular resistance (pvr) mean pulmonary arterial pressure (mpap) pulmonary hypertension (ph) inhaled treprostinil sarcoidosis
the effects of type of exercise in non-alcoholic fatty liver disease

Conditions: Non-alcoholic Fatty Liver Disease

Summary: the type of physical activity such as, aerobic or resistant exercise required to reduce liver fat content in patient with non-alcoholic fatty liver disease (nafld) remains unclear. the purpose of this study is to determine whether aerobic exercise should provide improvement of hepatic fat content and inflammation as well as metabolic profiles and anthropometric parameters better than resistant exercise.

increasing prevalence of overweight and obese worldwide, non-alcoholic fatty liver disease (nafld) is commonly diagnosed in daily clinical practice. weight reduction has been the only strategy established thus far to reduce hepatic lipid levels. thus, dietary restriction and exercise focusing on weight reduction is recommended as the cornerstone for managing nafld. recent reports have indicated that increased exercise greatly reduces hepatic fat accumulation and inflammation and the related oxidative stress levels outweigh those achieved by dietary restriction alone. clear guidelines for such a "lifestyle physical activity" for nafld management are currently lacking. the type of physical activity such as, aerobic or resistant exercise required to reduce liver fat content remains unclear.the purpose of this study is to determine whether aerobic exercise should provide improvement of hepatic fat content and inflammation as well as metabolic profiles and anthropometric parameters better than resistant exercise.

Eligibility criteria:
inclusion criteria: * siriraj medical personals * ultrasonography show liver steatosis by using ultrasound criteria * transient elastography by using the controlled attenuation parameter show moderate degree of fatty accumulation in the liver * history of alcohol consumption in male \<20 g/d, female \<10 g/d exclusion criteria: * liver disease of other etiology * medications that caused fatty accumulation in the liver * treated with vitamin e or antidiabetic agents * cardiopulmonary diseases or orthopedic conditions that are contraindicated for exercise

Keywords: aminotransferase fibrosis, liver anthropometry exercise
ct-2103 in treating patients with recurrent ovarian epithelial or fallopian tube cancer or primary peritoneal cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase i/ii trial to study the effectiveness of ct-2103 in treating patients who have recurrent ovarian epithelial or fallopian tube cancer or primary peritoneal cancer.

objectives: * determine the response rate and time to treatment failure in patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma treated with ct-2103. * determine the tolerability and safety of the previously established dose and schedule of ct-2103 in these patients. outline: this is a dose-escalation study. patients receive ct-2103 iv over 10 minutes on day 1. treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. if no more than 1 of the first 6 patients experience dose-limiting toxicity, then the remaining patients receive a higher dose of ct-2103. patients are followed between 1-3 months and then every 3 months thereafter. projected accrual: a total of 20-40 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma * recurrent disease following prior initial therapy with platinum-based regimen * no more than 2 prior cytotoxic chemotherapy regimens for recurrent disease * no more than 1 prior non-platinum, non-taxane regimen * at least 1 site of radiographically measurable disease and/or * ca-125 levels at least 50% above upper limits of normal for a minimum of 2 samples patient characteristics: age * not specified performance status * karnofsky 70-100% life expectancy * not specified hematopoietic * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 hepatic * bilirubin less than 1.5 times upper limit of normal (uln) * sgot less than 1.5 times uln * alkaline phosphatase less than 1.5 times uln renal * creatinine no greater than 1.5 mg/dl other * no unresolved, pre-existing grade 2 or greater neurotoxicity from prior treatment with neurotoxic drugs * no active uncontrolled infection * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for 4 weeks after study prior concurrent therapy: biologic therapy * at least 4 weeks since prior immunotherapy and recovered chemotherapy * see disease characteristics * at least 4 weeks since prior chemotherapy and recovered endocrine therapy * at least 4 weeks since prior endocrine therapy and recovered radiotherapy * at least 4 weeks since prior radiotherapy (except for palliative reasons) and recovered surgery * not specified other * at least 4 weeks since other prior investigational drugs and recovered

Keywords: recurrent ovarian epithelial cancer fallopian tube cancer primary peritoneal cavity cancer
clinico-biological collection of subjects with hyper lipoprotein a in reunion island

Conditions: Cardiovascular Disease

Summary: cardiovascular disease (cvd) is the second leading cause of death in france and the leading cause of death on reunion island. some modifiable risk factors for cardiovascular diseases are well identified and can be easily modulated, in particular by hygiene and dietetic measures (tobacco, sedentary lifestyle). other risk factors such as high blood pressure, diabetes or dyslipidemia can also be pharmacologically modulated. on the other hand, there is a cardiovascular risk factor that we do not know how to modulate: a high level of lipoprotein (a) (lp (a)), whose regulation remains largely unknown. high plasma levels of lipoprotein (a) remain a major risk for the development of cardiovascular disease and its clinical complications, which no drug can currently reduce. understanding the biological and genetic determinants modulating lp (a) levels remains a major challenge for treating subjects with hyper lp (a). several individuals and possibly reunion families have been detected as having abnormally high rates of apo (a) thanks to the link between cardiovascular clinical picture, lp (a) concentration and other biological markers, the study should allow a better understanding of the mechanisms underlying the cardiovascular risk in order to offer advice. prevention and care of at-risk subjects screened; or even avenues for adapted genetic counseling (dna sequencing). at the genetic level, several hypotheses could be explored making it possible to link the expression of the apo (a) protein to the genotype, in particular the presence of mutations in the gene, in the promoter region, polymorphisms, or epistatic regulation.


Eligibility criteria:
inclusion criteria: * patient with lp (a)\> 200 nmol / l or member of family of a patient with lp (a)\> 200 nmol / l * be affiliated or beneficiary of a social security scheme * signed consent exclusion criteria: * refusal to participate
liraglutide in newly onset type 1 diabetes.

Conditions: Diabetes Mellitus, Type 1

Summary: the purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.


Eligibility criteria:
inclusion criteria: * type 1 diabetes according to who criteria diagnosed ≤ 6 weeks before visit 0 * age 18 - 40 years - both inclusive * postprandial c-peptide \> 0.2 nmol/l following sustacal meal test * able to understand the written patient information and to give informed consent exclusion criteria: * type 2 diabetes * body mass index \<20 kg/m2 * pregnancy or unwillingness to use safe contraceptives * compromised kidney function (egfr \< 60 ml/min/1,73m2), dialysis or kidney transplantation at visit 0 * liver disease with elevated plasma alanine aminotransferase (alt) \> three times the upper limit of normal at visit 0

Keywords: c-peptide insulin hypoglycemia newly onset diabetes type 1 beta cell autoimmune glucagon meal test
hypothermic oxygenated machine perfusion of extended criteria kidney allografts from brain death donors

Conditions: Reperfusion Injury; Hypothermic Oxygenated Machine Perfusion

Summary: kidney transplantation (kt) has emerged as the mainstay of treatment for end-stage kidney disease. in an effort to address the widening gap between demand and supply of donor organs, there has been an increase in the numbers of "marginal" or functionally impaired renal allografts that had to be accepted for kt over the decades. the use of extended criteria donor (ecd) allografts is associated with a higher incidence of primary graft non-function (pnf) and/or delayed graft function (dgf). hypothermic oxygenated machine perfusion (hope) has been successfully tested in pre-clinical experiments and in a few clinical series of donation after cardiac death (dcd) in liver transplantation. the present trial is an investigator-initiated pilot study on the effects of hope on ecd-allografts in donation after brain death (dbd) kt. fifteen kidney allografts will be submitted to 2 hours of hope before implantation and are going to be compared to a case matched group transplanted after conventional cold storage (ccs).

the present trial is an investigator-initiated pilot study on the effects of hope on ecd-allografts in dbd kt. fifteen kidney allografts with defined inclusion/exclusion criteria will be submitted to 2 hours of hope via the renal artery before implantation and are going to be compared to a case matched group of 30 patients (1:2 matching) transplanted after ccs. besides the clinical evaluation of hope-"reconditioned" allograft function, a targeted biomarker analysis is planned using tissue, serum, and urine samples as the translational and basic research aspect of the present study.

Eligibility criteria:
inclusion criteria: dialysis-requiring patients, suffering from end stage kidney disease, listed for kt and receiving ecd organs at the department of surgery and transplantation, university hospital rwth aachen, aachen, germany. informed consent is obtained from all subjects participating in the trial by a qualified member of the study team. ecd is defined as followed: deceased donors \> 60 years and older, and those aged between 50-59 years with at least two of the following conditions: cerebrovascular cause of death, serum creatinine greater than 1.5 mg/dl (132.6 µmol/l), history of arterial hypertension exclusion criteria: 1. recipients of living donor kidney transplants 2. previous kidney transplantation 3. participation in other kidney related trials 4. the subject received an investigational drug within 30 days prior to inclusion 5. the subject is unwilling or unable to follow the procedures outlined in the protocol 6. the subject is mentally or legally incapacitated 7. non-german or non-english speakers 8. family members of the investigators or employees of the participating department 9. the subject is mentally or legally incapacitated 10. the subject suffers from uncontrolled bacterial or viral infection

Keywords: extended criteria donor donation after brain death hope kidney transplantation
lipid efficacy study (0524b-022)(completed)

Conditions: Primary Hypercholesterolemia; Mixed Hyperlipidemia

Summary: this is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered mk0524b on lipids. there will be 6 scheduled clinic visits, and 7 treatment arms.


Eligibility criteria:
inclusion criteria: * patients 18 to 85 years of age with primary hypercholesterolemia or mixed hyperlipidemia * ldl-c between 130 and 190 mg/l (category i) and 130 and 160 mg/l (category ii) and triglycerides \</= 350 mg/dl. exclusion criteria: * a condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study * patients with \<80% compliance * patients with certain medical conditions * patients taking certain concomitant medications and/or with unstable doses of medications * or those with a history of chd/chd equivalent or diabetes
trial for prevention of contrast nephropathy with sodium bicarbonate

Conditions: Contrast Induced Nephropathy; Kidney Diseases

Summary: contrast nephropathy (cn) is a common cause of renal failure associated with prolonged hospitalization, significant morbidity/mortality, and cost. in addition, these patients may require temporary or permanent hemodialysis which, in turn, is associated with further morbidity, mortality, and cost. cn has been reported to account for 10% of hospital acquired renal failure. in recent years, studies have investigated preventive therapies with mixed results. fenoldopam was found to be ineffective in a large randomized trial. dopamine has been shown to be ineffective as a preventive strategy. hemofiltration has been shown to be beneficial (new england journal of medicine \[nejm\] 2003) but is costly and not practical. mucomyst has shown mixed results. the single strategy which most would agree as being beneficial remains hydration, most commonly with intravenous 0.9% normal saline. most recently, sodium bicarbonate has been shown to be beneficial in a small randomized trial (n=119). it is clear that the most cost effective strategies for treatment of cn should be aimed at prevention. the general question is: "is a sodium bicarbonate solution more efficacious in preventing contrast nephropathy compared to normal saline?" the general hypothesis is that sodium bicarbonate will be more efficacious.


Eligibility criteria:
inclusion criteria: * gfr \< 60 ml/min/1.73m2. gfr will be adjusted by a correction factor as reported by our laboratory for patients self identifying as black. * \> 18 years and have at least one of the following risk factors for contrast nephropathy: diabetes (type 2), congestive heart failure, hypertension (\> 140/90), or age \> 75. * both inpatients and outpatients will be offered enrollment. exclusion criteria: * patients unable to give consent * already receiving sodium bicarbonate solution * undergoing emergency cardiac catheterization * receiving a contrast agent other than oxilan * on hemodialysis * recent exposure to contrast within 2 days * pulmonary edema * active congestive heart failure * severe valvular abnormality * recent significant change in kidney function (\> 15% over 2d) * one kidney * kidney transplant status

Keywords: contrast induced nephropathy sodium bicarbonate cardiac catheterization
neurorehabilitation using a virtual reality-based mirror therapy

Conditions: Rehabilitation, Mirror Neurons, Stroke

Summary: in the proposed study, the investigators assumed that mirror therapy combined with virtual reality technology will provide a better treatment effects than traditional mirror therapy for the patients with unilateral stroke. the aim of the study is to examine the difference in the treatment effects among the combination of task-oriented training with either virtual reality based mirror therapy, mirror therapy or traditional occupational therapy on the upper extremity function and brain activity of the stroke patients.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of stroke with unilateral side involved; 2. a score of mini-mental state examination greater than 24 for proving higher mental function; 3. time of onset \> 6 months before treatment begins, and 4. premorbid right-handedness. exclusion criteria: 1. vision loss; 2. major cognitive-perceptual deficit; 3. other brain disease.